Iovance Biotherapeutics' stock faces scrutiny over its current valuation. This follows a 421.3% return over the past year.
The company is a clinical-stage biotech focused on cell therapies. Its valuation relies heavily on investor perception of its revenue base and future sales potential.
The stock trades at a price-to-sales ratio of 15.3x. This ratio sits above the broader biotech sector average.
The stock reached a new 52-week high on Friday, September 25. This followed an upgrade to a 'strong-buy' rating. Goldman Sachs issued the upgrade.
Investors debate if the company's pipeline, commercial execution, and financial standing justify its premium valuation. This valuation is based on current revenue generation.